TABLE 1.
Demographic parameters for serosurveys in September 2021 and March 2022
| Serosurvey in September 2021 (n = 1,064) | Serosurvey in March 2022 (n = 1,397) | |
|---|---|---|
| Gender, n (%) | ||
| Female | 558 (52.44) | 794 (56.84) |
| Male | 467 (43.89) | 570 (40.8) |
| Others | 13 (1.22) | 22 (1.57) |
| Missing | 26 (2.44) | 11 (0.79) |
| Age, n (%) | ||
| 18–49 | 988 (92.86) | 1,186 (84.9) |
| ≥50 | 42 (3.95) | 184 (13.17) |
| Missing | 34 (3.2) | 27 (1.93) |
| Race, n (%) | ||
| White | 521 (48.97) | 656 (46.96) |
| Asian | 295 (27.73) | 393 (28.13) |
| Mixed | 51 (4.79) | 100 (7.16) |
| Black | 26 (2.44) | 37 (2.65) |
| Native | 14 (1.32) | 9 (0.64%) |
| Other | 105 (9.87) | 37 (2.65) |
| Prefer not to say | 9 (0.85) | 0 (0) |
| Missing | 27 (2.54) | 11 (0.79) |
| Vaccination status | ||
| Yes | 978 (91.92) | 1,323 (94.7) |
| No | 82 (7.71) | 61 (4.37) |
| Missing | 4 (0.38) | 13 (0.93) |
| Vaccine source | ||
| Pfizer | 510 (47.93) | 668 (47.82) |
| Moderna | 309 (29.04) | 443 (31.71) |
| Janssen | 94 (8.83) | 93 (6.66) |
| AstraZeneca | 46 (4.32) | 97 (6.94) |
| Attenuated virus | 12 (1.13) | 16 (1.14) |
| Missing | 93 (8.74) | 80 (5.73) |
| Previous COVID-19 infection | ||
| Yes | 205 (19.27) | 529 (37.87) |
| No | 857 (80.55) | 853 (61.06) |
| Missing | 2 (0.19) | 15 (1.07) |